TIF, a worldwide organization dedicated to ensuring equal access to quality healthcare for every patient with thalassaemia and other haemoglobin disorders across the world, and Hemanext Inc., a privately held medical technology company dedicated to improving patients’ quality of life by delivering a better red blood cell (RBC) replacement therapy, announce today a new strategic alliance on behalf of people living with thalassaemia.
TIF and Hemanext are committed to helping elevate the standard of care for thalassaemia patients worldwide, through education and research and development initiatives that will lead to important clinical advances. Through this new partnership, Hemanext will support TIF’s educational and advocacy activities in support of patients, caregivers, healthcare providers and policymakers worldwide.
More than 600,000 people worldwide have one of many types of thalassaemia, all of which are inherited blood disorders that are characterized by decreased production of hemoglobin, the protein found in RBCs that carries oxygen to cells throughout the body. The disease causes the destruction of red blood cells leading to anemia. As such, blood transfusions play a vital role in the treatment and management of thalassaemia and other haemoglobin disorders.
Hemanext is seeking to maximize the therapeutic value of transfusions and reduce financial burdens to health systems with its novel RBC replacement technology. Hemanext is developing a new hypoxic storage method, which the company and many researchers and clinicians believe might improve the quality of life for patients that require chronic and high-volume transfusions, including people with thalassaemia and other haemoglobin disorders. Optimizing transfusions is critically important at this time, as societies around the world attempt to preserve and expand the blood supply.
”TIF is pleased that Hemanext shares our goal to develop new treatments for hemoglobin disorders. We welcome Hemanext into our network of industry partners”, Dr Androulla Eleftheriou, TIF Executive Director, stated with regard to this strategic new partnership, while Hemanext President and CEO, Mr Martin Cannon added that ”Working with researchers in the U.S. and Europe, we are developing a technology that we think will deliver a higher-quality, more uniform red blood cell. We applaud TIF for its support of treatments in every country impacted by thalassaemia and other haemoglobin disorders.”